DUBLIN – Maze Therapeutics Inc. recently secured $191 million in initial funding to join the ranks of biotechnology firms that aim to uncover new biology and new drug targets by sifting through large volumes of genomic and phenotypic data and testing the hypotheses those analyses generate by carrying out genome-wide perturbations within cellular disease models.